EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations

Valentina Fainardi, Federico Cresta, Claudio Sorio iD, Paola Melotti, Emanuela Pesce, Michela Deolmi iD, Francesco Longo, Kleinfelder Karina, Susanna Esposito, Giovanna Pisi

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27211 ↗

At a glance

Beobachtungsstudie in Pediatric Pulmonology, 2024. Written by Valentina Fainardi and 9 co-authors. Institution: Department of Medicine and Surgery, Cystic Fibrosis Unit, Pediatric Clinic, Parma, Italy. Major MEDLINE topics: Cystic Fibrosis, Benzodioxoles, Aminophenols, Cystic Fibrosis Transmembrane Conductance Regulator. Cited 7 times so far (Crossref); 23 references. Funded by: None.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

The triple combination of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved the outcome of people with Cystic Fibrosis (pwCF) with at least one F508del mutation. However, carriers of rare cystic fibrosis transmembrane conductance regulator (CFTR) variants are not candidates for this innovative treatment.

Methods

In this observational study, we report the results of the compassionate use of ETI in 10 pwCF carriers of rare mutations after 2 months of treatment. Rectal organoids and short‐term cultures of nasal epithelium obtained from rectal suction biopsies and nasal brushing were obtained from four subjects.

Results

After 2 months of ETI, all patients (4 males, mean age 30.1 ± 13.3 years) showed a significant increase of FEV 1 % predicted values [+8.0 (3.5–12.7) %, p < 0.010], body mass index [+0.85 (0–1.22) kg/m 2 , p < 0.020] and cystic fibrosis questionnaire‐revised [+19.5 (6.3–29.2) points, p < 0.009]. A significant decrease of sweat chloride concentration [–11.2 (–1.7 to −34.0) mmol/L, p < 0.020] and exacerbations [–1.5 (–2 to –1), p < 0.008] was also recorded. Overall, 7 out of 10 participants were considered full responders. All patients reported cough disappearance ( n = 3) or reduction ( n = 7). Long‐term oxygen was discontinued in two out of three patients and one also stopped noninvasive ventilation and was removed from the lung transplantation waiting list.

Conclusions

Despite the limited number of cases, our results support the use of CFTR modulators in patients with rare CFTR variants that are not currently approved for ETI in Europe.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisBenzodioxolesAminophenolsCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinolonesPyridinesPyrazolesDrug CombinationsMutationHumansMaleFemaleAdultYoung AdultPyrrolidinesAdolescentCompassionate Use TrialsChloride Channel AgonistsTreatment Outcome

Author keywords

ETIcell culturecystic fibrosiselexacaftor/tezacaftor/ivacaftormodulatororganoidorganoidsrare mutationsrare variantstheratyping

Substances

BenzodioxolesAminophenolsCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinoloneselexacaftorPyridinesPyrazolesDrug Combinationstezacaftor

Authors and institutions

  • Department of Medicine and Surgery, Cystic Fibrosis Unit, Pediatric Clinic, Parma, Italy.
  • UOSD Centro Fibrosi Cistica, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Cystic Fibrosis Laboratory D. Lissandrini, Department of Medicine, Division of General Pathology, University of Verona, Verona, Italy.
  • Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • IRCCS Istituto Giannina Gaslini, UOC Genetica Medica, Genova, Italy.
  • Cystic Fibrosis Unit, Pediatric Clinics, University Hospital of Parma, Parma, Italy.

ORCID profiles: Claudio Sorio, Michela Deolmi

Funding

  • None

Cite

APA

Fainardi, V., Cresta, F., Sorio, C., Melotti, P., Pesce, E., Deolmi, M., Longo, F., Karina, K., Esposito, S., & Pisi, G. (2024). Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27211

Vancouver

Fainardi V, Cresta F, Sorio C, Melotti P, Pesce E, Deolmi M, et al. Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27211

BibTeX
@article{Fainardi2024,
  author = {Fainardi, Valentina and Cresta, Federico and Sorio, Claudio and Melotti, Paola and Pesce, Emanuela and Deolmi, Michela and Longo, Francesco and Karina, Kleinfelder and Esposito, Susanna and Pisi, Giovanna},
  title = {Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27211}
}
Start for free →